Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma

被引:92
作者
De Brabandere, Marisol [1 ]
Mousa, Amr Gaber [2 ]
Nulens, An [1 ]
Swinnen, Ans [1 ]
Van Limbergen, Erik [1 ]
机构
[1] Univ Hosp Leuven, Dept Radiat Oncol, Louvain, Belgium
[2] Cairo Univ, Natl Canc Inst, Dept Radiat Therapy, Cairo, Egypt
关键词
brachytherapy; cervix; optimisation; MRI;
D O I
10.1016/j.radonc.2007.10.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: In this study on PDR treatment planning of utero-vaginal carcinoma, we analysed the dosimetry of traditional X-ray based plans as it presents on MR images. The potential gain of MRI-based dose optimisation was assessed. Patients and methods: Sixteen patients boosted with PDR brachytherapy after external beam therapy were included. The clinical X-ray based plans were projected on MR images. The GTV, HR-CTV and IR-CTV were retrospectively contoured, as well as the bladder, rectum and sigmoid colon. The dose in the critical organs and target coverage was investigated. In a second phase, the plans were manually optimised using the MR information. The objectives were to lower the dose in the critical organs (<= 85 Gy(alpha beta 3) for bladder, <= 75 Gy(alpha beta 3) for rectum and sigmoid colon) and to increase the HR-CTV dose to D90 >= 85 Gy(alpha beta 10). Results: In the X-ray based plans, D-2cc in bladder and sigmoid colon exceeded the tolerance doses in 10/16 and 7/16 patients, respectively. Coverage of the IR-CTV with the 60 Gy(alpha beta 10) was acceptable. D90 of the HR-CTV was below 85 Gy(alpha beta 10) in 13 out of 16 patients. After optimisation, the dose constraints in the OAR were not exceeded anymore in any patient. The average D-2cc dose reduction was 7 +/- 6 Gy(alpha beta 3) in the bladder and 7 +/- 4 Gy(alpha beta 3) in the sigmoid colon for those patients in which the dose constraint was initially exceeded. In addition, an average dose increase of 3 Gy(alpha beta 10) was accomplished in the HR-CTV. Conclusions: MRI-based dose optimisation can play an important role to reduce the dose delivered to the critical organs and to improve target coverage. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:217 / 226
页数:10
相关论文
共 30 条
[1]   MAXIMUM AND MEAN BLADDER DOSE DEFINED FROM ULTRASONOGRAPHY - COMPARISON WITH THE ICRU REFERENCE IN GYNECOLOGICAL BRACHYTHERAPY [J].
BARILLOT, I ;
HORIOT, JC ;
MAINGON, P ;
BONELEPINOY, MC ;
VAILLANT, D ;
FEUTRAY, S .
RADIOTHERAPY AND ONCOLOGY, 1994, 30 (03) :231-238
[4]  
DECKER WE, 2005, INT J RADIAT ONCOL, V50, P561
[5]  
Dimopoulos J, 2006, RADIOTHER ONCOL, V81, pS39
[6]   The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:: Clinical feasibility and preliminary results [J].
Dimopoulos, Johannes C. A. ;
Kirisits, Christian ;
Petric, Primoz ;
Georg, Petra ;
Lang, Stefan ;
Berger, Daniel ;
Poetter, Richard .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01) :83-90
[7]   Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects [J].
Fellner, C ;
Pötter, R ;
Knocke, TH ;
Wambersie, A .
RADIOTHERAPY AND ONCOLOGY, 2001, 58 (01) :53-62
[8]  
FOWLER JF, 1990, BRACHYTHERAPY, P121
[9]  
Georg P, 2006, RADIOTHER ONCOL, V81, pS38
[10]   Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group* (I):: concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV [J].
Haie-Meder, C ;
Pötter, R ;
Van Limbergen, E ;
Briot, E ;
De Brabandere, M ;
Dimopoulos, J ;
Dumas, I ;
Hellebust, TP ;
Kirisits, C ;
Lang, SF ;
Muschitz, S ;
Nevinson, J ;
Nulens, A ;
Petrow, P ;
Wachter-Gerstner, N .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) :235-245